AR092959A1 - Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales - Google Patents
Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades viralesInfo
- Publication number
- AR092959A1 AR092959A1 ARP130103665A ARP130103665A AR092959A1 AR 092959 A1 AR092959 A1 AR 092959A1 AR P130103665 A ARP130103665 A AR P130103665A AR P130103665 A ARP130103665 A AR P130103665A AR 092959 A1 AR092959 A1 AR 092959A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- alkylene
- cycloalkyl
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un compuesto que tiene la fórmula (1), o una sal farmacéuticamente aceptable del mismo, en la que: B es un compuesto de fórmula (2) ó (3); X es O, N, S o CH₂; R¹ es H, o un compuesto de fórmula (4), (5), (6) ó (7); R² es H, -C(O)-(alquilo C₁₋₂₀), -C(O)-(cicloalquilo C₃₋₆), -C(O)O-(alquilo C₁₋₂₀), -C(O)O-(cicloalquilo C₃₋₆), -C(O)NH-(alquilo C₁₋₂₀), -C(O)NH-(cicloalquilo C₃₋₆) o el resto de fórmula (7), o R¹ y R² se unen para formar un grupo que tiene la fórmula (8); R³ es -CN, -N₃ o -CºCH; R⁴ es H, alquilo C₁₋₆, cicloalquilo C₃₋₇, fenilo o bencilo, en el que dicho alquilo C₁₋₆ puede estar opcionalmente sustituido con un grupo seleccionado entre halo, -OR¹², -SR¹², guanidino, -N(R¹²)₂, -C(O)OR¹², -C(O)N(R¹²)₂, -NHC(O)R¹², heteroarilo monocíclico de 5 ó 6 miembros y heteroarilo bicíclico de 9 ó 10 miembros, y en el que dicho grupo fenilo y dicho grupo bencilo pueden estar opcionalmente sustituidos con hasta 2 grupos, cada uno seleccionado independientemente entre alquilo C₁₋₆, halo y -OR¹²; R⁵ es H, alquilo C₁₋₆, cicloalquilo C₃₋₇, fenilo o bencilo, en el que dicho alquilo C₁₋₆ puede estar opcionalmente sustituido con un grupo seleccionado entre halo, -OR¹², -SR¹², guanidino, -N(R¹²)₂, -C(O)OR¹², -C(O)N(R¹²)₂, -NHC(O)R¹², heteroarilo monocíclico de 5 ó 6 miembros y heteroarilo bicíclico de 9 ó 10 miembros, y en el que dicho grupo fenilo y dicho grupo bencilo pueden estar opcionalmente sustituidos con hasta 2 grupos, cada uno seleccionado independientemente entre alquilo C₁₋₆, halo y -OR¹²; R⁶ es H, alquilo C₁₋₂₀, alquenilo C₂₋₂₀, -(alquileno C₁₋₃)ₘ-(cicloalquilo C₃₋₇), -(alquileno C₁₋₃)ₘ-(arilo C₆₋₁₀) o -(alquileno C₁₋₃)ₘ-adamantilo, en el que dicho grupo alquilo C₁₋₂₀, dicho grupo alquenilo C₂₋₂₀, dicho grupo arilo C₆₋₁₀ y dicho grupo adamantilo pueden estar opcionalmente sustituidos hasta con tres grupos, cada uno seleccionado independientemente entre halo, -OR¹², -C(O)OR¹², CN, NO₂, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo C₃₋₇, arilo C₆₋₁₀, heteroarilo monocíclico de 5 ó 6 miembros, heteroarilo bicíclico de 9 ó 10 miembros, -N(R¹²)₂, -C(O)N(R¹²)₂ -SR¹², -S(O)R¹², -S(O)₂R¹², -S(O)₂N(R¹²)₂, -NHC(O)R¹², -NHC(O)OR¹² y -NC(O)N(R¹²)₂; R⁷ es H, arilo C₆₋₁₀, heteroarilo monocíclico de 5 ó 6 miembros, heteroarilo bicíclico de 9 ó 10 miembros, o -(alquileno C₁₋₃)-C(O)O-(alquilo C₁₋₆), en el que dicho grupo arilo C₆₋₁₀, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros y dicho grupo heteroarilo bicíclico de 9 ó 10 miembros pueden estar opcionalmente sustituidos con R¹³; R⁸ es H o -C(O)-(alquilo C₁₋₂₀); R¹¹ es H, alquilo C₁₋₂₀, alquenilo C₂₋₂₀, -(alquileno C₁₋₃)ₘ-(cicloalquilo C₃₋₇), cicloalquilo C₃₋₇, -(alquileno C₁₋₃)ₘ-arilo C₆₋₁₀ o -(alquileno C₁₋₃)ₘ-adamantilo, heteroarilo monocíclico de 5 ó 6 miembros, heteroarilo bicíclico de 9 ó 10 miembros, en el que dicho grupo alquilo C₁₋₂₀, dicho grupo alquenilo C₂₋₂₀, dicho grupo arilo C₆₋₁₀, dicho grupo adamantilo, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros y dicho grupo heteroarilo bicíclico de 9 ó 10 miembros pueden estar opcionalmente sustituidos con hasta cinco grupos, cada uno seleccionado independientemente entre alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₇, arilo C₆₋₁₀, heteroarilo monocíclico de 5 ó 6 miembros, heteroarilo bicíclico de 9 ó 10 miembros, halo, -OR¹², -SR¹², -S(O)R¹², -S(O)₂R¹², -S(O)₂N(R¹²)₂, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, -O-(haloalquilo C₁₋₆), -CN, -NO₂, -N(R¹²)₂, -C(O)OR¹², -C(O)N(R¹²)₂ y -NHC(O)R¹², -NHC(O)OR¹² y -NHC(O)N(R¹²)₂; cada aparición de R¹² es independientemente H, alquilo C₁₋₁₀, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, -(alquileno C₁₋₃)ₘ-(cicloalquilo C₃₋₇), -(alquileno C₁₋₃)ₘ-(arilo C₆₋₁₀), -(alquileno C₁₋₃)ₘ-(heterocicloalquilo de 4 a 7 miembros), -(alquileno C₁₋₃)ₘ-(heteroarilo monocíclico de 5 ó 6 miembros) o -(alquileno C₁₋₃)ₘ-(heteroarilo bicíclico de 9 ó 10 miembros), en el que dicho grupo cicloalquilo C₃₋₇, dicho grupo arilo C₆₋₁₀, dicho grupo heterocicloalquilo de 4 a 7 miembros, dicho grupo heteroarilo monocíclico de 5 ó 6 miembros o dicho grupo heteroarilo bicíclico de 9 ó 10 miembros puede estar opcionalmente sustituido con R¹⁶; R¹³ representa de uno a cinco grupos sustituyentes, cada uno seleccionado independientemente entre alquilo C₁₋₆, halo, -OR¹², -SR¹², haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, -O-(haloalquilo C₁₋₆), -CN, -NO₂, -N(R¹²)₂, -C(O)OR¹², -C(O)N(R¹²)₂ y -NHC(O)R¹², o dos grupos R¹³ cualesquiera en átomos de carbono adyacentes en el anillo se pueden combinar para formar -O-R¹⁴-O-; R¹⁴ es -[C(R¹⁵)₂]ₙ-; cada aparición de R¹⁵ es independientemente H o alquilo C₁₋₆; R¹⁶ representa de uno a cinco grupos sustituyentes, cada uno seleccionado independientemente entre alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, halo, -OR¹⁷, -SR¹⁷, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, -O-(haloalquilo C₁₋₆), -CN, -NO₂, -N(R¹⁷)₂, -C(O)OR¹⁷, -C(O)N(R¹⁷)₂ y -NHC(O)R¹⁷; cada aparición de R¹⁷ es independientemente H, alquilo C₁₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, -(alquileno C₁₋₃)ₘ-(cicloalquilo C₃₋₇), -(alquileno C₁₋₃)ₘ-(arilo C₆₋₁₀), -(alquileno C₁₋₃)ₘ-(heterocicloalquilo de 4 a 7 miembros), -(alquileno C₁₋₃)ₘ-(heteroarilo monocíclico de 5 ó 6 miembros) o -(alquileno C₁₋₃)ₘ-(heteroarilo bicíclico de 9 ó 10 miembros); cada aparición de m es independientemente 0 ó 1, y cada aparición de n es independientemente 1, 2 ó 3.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261715035P | 2012-10-17 | 2012-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092959A1 true AR092959A1 (es) | 2015-05-06 |
Family
ID=49943490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130103665A AR092959A1 (es) | 2012-10-17 | 2013-10-09 | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
Country Status (5)
Country | Link |
---|---|
US (1) | US20140128339A1 (es) |
EP (1) | EP2909221A1 (es) |
AR (1) | AR092959A1 (es) |
TW (1) | TW201418274A (es) |
WO (1) | WO2014062596A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
YU92202A (sh) | 2000-05-26 | 2006-01-16 | Idenix (Cayman) Limited | Metode i smeše za lečenje flavi virusa i pesti virusa |
CN1849142A (zh) | 2002-11-15 | 2006-10-18 | 埃迪尼克斯(开曼)有限公司 | 2′-支链核苷和黄病毒突变 |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
CN103842369A (zh) | 2011-03-31 | 2014-06-04 | 埃迪尼克斯医药公司 | 用于治疗病毒感染的化合物和药物组合物 |
EP2731434A4 (en) | 2011-07-13 | 2014-12-31 | Merck Sharp & Dohme | 5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES |
US9408863B2 (en) | 2011-07-13 | 2016-08-09 | Merck Sharp & Dohme Corp. | 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases |
TW201329096A (zh) | 2011-09-12 | 2013-07-16 | Idenix Pharmaceuticals Inc | 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物 |
NZ702744A (en) | 2012-05-22 | 2016-12-23 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
WO2013177195A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphate prodrugs for hcv infection |
WO2013177188A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
WO2013174962A1 (en) | 2012-05-25 | 2013-11-28 | Janssen R&D Ireland | Uracyl spirooxetane nucleosides |
EP2900682A1 (en) | 2012-09-27 | 2015-08-05 | IDENIX Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
KR102001280B1 (ko) | 2012-10-08 | 2019-07-17 | 아이데닉스 파마슈티칼스 엘엘씨 | Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체 |
US9211300B2 (en) | 2012-12-19 | 2015-12-15 | Idenix Pharmaceuticals Llc | 4′-fluoro nucleosides for the treatment of HCV |
US9309275B2 (en) | 2013-03-04 | 2016-04-12 | Idenix Pharmaceuticals Llc | 3′-deoxy nucleosides for the treatment of HCV |
US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
US9187515B2 (en) | 2013-04-01 | 2015-11-17 | Idenix Pharmaceuticals Llc | 2′,4′-fluoro nucleosides for the treatment of HCV |
US10005779B2 (en) | 2013-06-05 | 2018-06-26 | Idenix Pharmaceuticals Llc | 1′,4′-thio nucleosides for the treatment of HCV |
WO2015017713A1 (en) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
CN104119385B (zh) * | 2014-07-24 | 2017-04-05 | 廖国超 | 核苷类似物的磷酸酯前药及其应用 |
CN105294795B (zh) * | 2014-11-20 | 2019-01-15 | 南京曼杰生物科技有限公司 | 核苷氨基磷酸酯衍生物及其应用 |
WO2016123905A1 (en) * | 2015-02-06 | 2016-08-11 | Ginkgo Pharma Co., Ltd. | Novel phosphoramidates for treatment of hcv infection |
WO2016182939A1 (en) * | 2015-05-08 | 2016-11-17 | Abbvie Inc. | Anti-viral compounds |
WO2016182937A1 (en) * | 2015-05-08 | 2016-11-17 | Abbvie Inc. | Anti-viral compounds |
WO2016182934A1 (en) * | 2015-05-08 | 2016-11-17 | Abbvie Inc. | Anti-viral compounds |
WO2016182935A1 (en) * | 2015-05-08 | 2016-11-17 | Abbvie Inc. | Anti-viral compounds |
WO2016182936A1 (en) * | 2015-05-08 | 2016-11-17 | Abbvie Inc. | Anti-viral compounds |
WO2017040766A1 (en) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral tetrahydrofurane derivatives |
CN106977543A (zh) * | 2016-01-19 | 2017-07-25 | 上海医药工业研究院 | 改进的索非布韦中间体的制备工艺 |
WO2018093717A1 (en) * | 2016-11-17 | 2018-05-24 | Abbvie Inc. | Compositions and methods for treating hcv infection |
CN111491634A (zh) | 2017-07-31 | 2020-08-04 | 詹纽瑞治疗公司 | 有机磷酸酯衍生物 |
US11708637B2 (en) * | 2019-08-13 | 2023-07-25 | The Regents Of The University Of California | Methods of supporting a graphene sheet disposed on a frame support |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ20032005A3 (en) | 2001-01-22 | 2004-04-14 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
EP3521297B1 (en) * | 2003-05-30 | 2021-12-22 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
WO2005003047A1 (en) | 2003-07-03 | 2005-01-13 | Philips Intellectual Property & Standards Gmbh | Pane which can be heated by means of invisible light |
US20090081636A1 (en) | 2005-04-11 | 2009-03-26 | Mingjun Huang | Pharmaceutical compositions for and methods of inhibiting HCV replication |
AR056327A1 (es) * | 2005-04-25 | 2007-10-03 | Genelabs Tech Inc | Compuestos de nucleosidos para el tratamiento de infecciones virales |
AU2007215114A1 (en) | 2006-02-14 | 2007-08-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
ATE543808T1 (de) | 2006-12-22 | 2012-02-15 | Schering Corp | 5,6-ring-annelierte indolderivate und ihre verwendung |
WO2008082484A1 (en) | 2006-12-22 | 2008-07-10 | Schering Corporation | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
EP2064181A1 (en) | 2006-12-22 | 2009-06-03 | Schering Corporation | 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
US9003695B2 (en) | 2006-12-29 | 2015-04-14 | Genifuel Corporation | Controlled growth environments for algae cultivation |
BRPI0816116A2 (pt) | 2007-08-29 | 2015-03-03 | Schering Corp | Derivados de indol 2,3-substituídos para o tratamento de infecções virais. |
KR20100061819A (ko) | 2007-08-29 | 2010-06-09 | 쉐링 코포레이션 | 바이러스 감염 치료 또는 예방용 테트라사이클릭 인돌 유도체 및 이의 용도 |
CA2697500A1 (en) | 2007-08-29 | 2009-03-12 | Schering Corporation | 2,3-substituted azaindole derivatives for treating viral infections |
WO2009032124A1 (en) | 2007-08-29 | 2009-03-12 | Schering Corporation | Substituted indole derivatives and methods of use thereof |
NZ588400A (en) | 2008-04-23 | 2012-08-31 | Gilead Sciences Inc | 1'-substituted carba-nucleoside analogs for antiviral treatment |
EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
EP2310564B1 (en) | 2008-07-14 | 2017-05-31 | LG Electronics Inc. | Laundry treating apparatus |
WO2010075517A2 (en) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Nucleoside analogs |
NZ593648A (en) | 2008-12-23 | 2013-09-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
KR20130140219A (ko) | 2009-03-27 | 2013-12-23 | 머크 샤프 앤드 돔 코포레이션 | C형 간염 바이러스 복제의 억제제 |
RS55699B1 (sr) | 2009-09-21 | 2017-07-31 | Gilead Sciences | 2' -fluoro supstituisani karba-nukleozidni analozi zaantiviralno lečenje |
JP2014515023A (ja) * | 2011-04-13 | 2014-06-26 | メルク・シャープ・アンド・ドーム・コーポレーション | 2’−置換ヌクレオシド誘導体およびウイルス疾患の処置のためのその使用方法 |
US9150603B2 (en) * | 2011-04-13 | 2015-10-06 | Merck Sharp & Dohme Corp. | 2′-cyano substituted nucleoside derivatives and methods of use thereof useful for the treatment of viral diseases |
WO2012142075A1 (en) * | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
NZ702744A (en) * | 2012-05-22 | 2016-12-23 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
-
2013
- 2013-10-09 AR ARP130103665A patent/AR092959A1/es unknown
- 2013-10-15 WO PCT/US2013/064906 patent/WO2014062596A1/en active Application Filing
- 2013-10-15 US US14/054,424 patent/US20140128339A1/en not_active Abandoned
- 2013-10-15 EP EP13818854.5A patent/EP2909221A1/en not_active Withdrawn
- 2013-10-16 TW TW102137357A patent/TW201418274A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2909221A1 (en) | 2015-08-26 |
WO2014062596A1 (en) | 2014-04-24 |
TW201418274A (zh) | 2014-05-16 |
US20140128339A1 (en) | 2014-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092959A1 (es) | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales | |
AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
AR095464A1 (es) | Compuestos de heteroarilo y usos de los mismos | |
AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR093036A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
AR089489A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
UY33775A (es) | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos | |
AR110088A1 (es) | Inhibidores de magl | |
AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
AR088760A1 (es) | Derivados de pirrolopirimidina y purina | |
AR099111A1 (es) | Derivados de azepano y su uso para tratar infecciones de hepatitis b | |
AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
AR100975A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
AR090589A1 (es) | INHIBIDORES DE b-LACTAMASA ISOXAZOL | |
AR100006A1 (es) | Derivados de tubulisina | |
AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |